Regorafenib

Regorafenib is an orally-administered inhibitor of multiple kinases. It is used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors, Tyrosine Kinase Inhibitors and VEGF inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Stivarga and Regorafenibum. Its PubChem CID is 11167602.

CAS No 755037-03-7
Molecular Formula C21H15ClF4N4O3
Molecular Weight 482.8 g/mol
Synonyms 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide

Frequently Asked Questions